Compliance Access and Quality System Perspective | Global Regulatory Barriers for Menghini Liver Biopsy Needle and Manners Technology’s Certification Layout Strategy

Compliance Access and Quality System Perspective | Global Regulatory Barriers for Menghini Liver Biopsy Needle and Manners Technology's Certification Layout Strategy

The Menghini Liver Biopsy Needle is classified as an invasive Class II medical device. It directly contacts human tissues and performs puncture sampling, making it a category under stringent supervision by drug regulatory authorities worldwide. ISO 9001:2015, ISO 13485, CE MDR, FDA 510(k) and NMPA registration constitute mandatory thresholds for manufacturers seeking access to the global market. Compliance capability is not only a prerequisite for product launch, but also a core indicator for brand credibility, hospital procurement and international bidding. By establishing a standardized quality system and adopting a forward‑looking compliance layout, Manners Technology has built market‑access barriers adaptable to global markets, setting a benchmark for the compliant development of domestic manufacturers.

The ISO 13485 quality management system, specifically designed for medical devices, forms the core foundation for the manufacturing of Menghini needles. This system covers the entire workflow, including raw material procurement, production and manufacturing, clean‑room control, sterilization validation, finished‑product inspection, warehousing and logistics, and customer complaint handling. It mandates documented control, batch traceability, risk assessment and change‑control mechanisms. Manners Technology has fully implemented both ISO 9001:2015 and ISO 13485 dual systems, and implements risk management from the design and development phase. This ensures that the entire product lifecycle - from R&D and mass production to after‑sales service - complies with international standards, serving as the core passport for market entry into Europe, the Americas, Southeast Asia, the Middle East and other regions.

Following the enforcement of EU MDR (2017/745), market‑access thresholds for invasive biopsy devices have risen sharply. As a short‑term invasive device, the Menghini needle must undergo four core procedures: technical documentation compilation, clinical evaluation, biocompatibility testing and notified body audit - a complex, lengthy and costly process. In the past, numerous small‑ and medium‑sized manufacturers were forced to exit the EU market due to inability to achieve MDR compliance. In contrast, Manners Technology proactively invested in regulatory interpretation, clinical data accumulation and notified‑body cooperation. It can provide CE MDR certification consultation and dossier preparation for customer‑specific products, enabling brand owners to quickly gain access to the EU market.

The U.S. FDA market centers on the 510(k) premarket notification pathway, requiring manufacturers to submit comprehensive data including substantial equivalence comparison, biocompatibility, sterilization validation and performance testing. The FDA imposes strict requirements on biopsy needles regarding negative‑pressure performance, cutting‑edge strength, sterility indicators and material safety - standards that most domestic enterprises cannot independently meet for registration. Leveraging robust in‑house testing capabilities and a dedicated compliance team, Manners Technology offers end‑to‑end technical support for FDA submissions, lowering barriers to U.S. market entry for brand owners.

In terms of domestic NMPA registration, with the acceleration of volume‑based procurement and domestic substitution for medical devices in China, the regulatory framework for liver biopsy needles - covering registration, modification, renewal and adverse‑event monitoring - has become increasingly stringent. Well‑versed in domestic registration regulations and testing requirements, Manners Technology supports brand owners throughout the full process, including registration testing, clinical trials and system inspections, ensuring smooth product approval and launch.

In summary, global competition for Menghini liver biopsy needles is essentially a competition of compliance systems. Only manufacturers with robust quality systems, certification expertise and risk‑management capabilities can achieve long‑term stable supply to the global market. Built on its dual‑system foundation and with continuous alignment to international regulations, Manners Technology serves as a key enabler for domestic interventional biopsy devices to expand globally.